ArticleCell reports. Medicine2024

DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.

Allison M Kirk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.